Prognostic Significance of miRNA Subtypes in Melanoma: A Survival Analysis and Correlation with Treatment Response Across Patient Stages DOI Creative Commons

Mihaela Prodan,

Alis Dema,

Bianca Natarâș

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2809 - 2809

Published: Dec. 11, 2024

Background and Objectives: Melanoma remains a leading cause of skin cancer mortality despite advancements in targeted therapies immunotherapies. MicroRNAs (miRNAs) have emerged as potential biomarkers for prognosis treatment response. This study aims to analyze survival outcomes according various miRNA subtypes, assess the association between specific miRNAs response, include patient staging evaluate their prognostic significance. Methods: A retrospective cohort was conducted on 90 patients from Pius Brinzeu County Emergency Clinical Hospital, Timisoara, 2019 2022. The included 45 with advanced-stage melanoma benign nevi. expression levels were quantified using miRNeasy Kit Human Cancer PathwayFinder miScript PCR Array. Survival analysis performed Kaplan–Meier method, Cox proportional hazards models used impact survival. Logistic regression analyzed markers adjusting staging. Results: Elevated hsa-miR-200a-3p hsa-miR-335-5p significantly associated poorer overall (p < 0.01), particularly stage III IV patients. Conversely, higher hsa-miR-451a correlated improved rates = 0.02). Patients increased hsa-miR-29b-3p showed better response immunotherapy (OR 2.35, 95% CI: 1.15–4.79). Multivariate confirmed that independent predictors Conclusions: Specific subtypes are significant melanoma, influencing responses across different stages. Incorporating profiling into clinical practice could enhance personalized strategies improve prognoses.

Language: Английский

Prognostic Significance of miRNA Subtypes in Melanoma: A Survival Analysis and Correlation with Treatment Response Across Patient Stages DOI Creative Commons

Mihaela Prodan,

Alis Dema,

Bianca Natarâș

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2809 - 2809

Published: Dec. 11, 2024

Background and Objectives: Melanoma remains a leading cause of skin cancer mortality despite advancements in targeted therapies immunotherapies. MicroRNAs (miRNAs) have emerged as potential biomarkers for prognosis treatment response. This study aims to analyze survival outcomes according various miRNA subtypes, assess the association between specific miRNAs response, include patient staging evaluate their prognostic significance. Methods: A retrospective cohort was conducted on 90 patients from Pius Brinzeu County Emergency Clinical Hospital, Timisoara, 2019 2022. The included 45 with advanced-stage melanoma benign nevi. expression levels were quantified using miRNeasy Kit Human Cancer PathwayFinder miScript PCR Array. Survival analysis performed Kaplan–Meier method, Cox proportional hazards models used impact survival. Logistic regression analyzed markers adjusting staging. Results: Elevated hsa-miR-200a-3p hsa-miR-335-5p significantly associated poorer overall (p < 0.01), particularly stage III IV patients. Conversely, higher hsa-miR-451a correlated improved rates = 0.02). Patients increased hsa-miR-29b-3p showed better response immunotherapy (OR 2.35, 95% CI: 1.15–4.79). Multivariate confirmed that independent predictors Conclusions: Specific subtypes are significant melanoma, influencing responses across different stages. Incorporating profiling into clinical practice could enhance personalized strategies improve prognoses.

Language: Английский

Citations

1